A PHASE 2, 16-WEEK, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS SAFETY, TOLERABILITY AND EFFICACY OF REPEATED DOSES OF KB001-A IN SUBJECTS INFECTED WITH P. AERUGINOSA

被引：0
|
作者：
Chmiel, J. [1 ]
Hamblett, N. M. [2 ]
Geller, D. [3 ]
Konstan, M. [1 ]
VanDevanter, D. [1 ]
Thompson, V [2 ]
Molfino, N. [3 ]
Yarranton, G. [3 ]
Shreeniwas, R. [3 ]
机构：
[1] Case Western Reserve Univ, Cleveland, OH 44106 USA
[2] Seattle Childrens Hosp, Seattle, WA USA
[3] KaloBios Pharmaceut Inc, San Francisco, CA USA
来源：
PEDIATRIC PULMONOLOGY | 2015年 / 50卷
关键词：
D O I：
暂无
中图分类号：
R72 [儿科学];
学科分类号：
100202 ;
摘要：
218
引用
收藏
页码：272 / 272
页数：1
相关论文
共 50 条
  • [1] A randomized, double-blind, placebo-controlled phase 2 study to assess safety, tolerability, and efficacy of RT001 in patients with amyotrophic lateral sclerosis
    Weemering, Daphne N.
    Midei, Mark
    Milner, Peter
    Gopalakrishnan, Vidhya
    Kumar, Anil
    Dannenberg, Andrew J.
    Bunte, Tommy M.
    Foucher, Juliette
    Ingre, Caroline
    Kenina, Viktorija
    Rallmann, Karin
    van den Berg, Leonard H.
    van Eijk, Ruben P. A.
    EUROPEAN JOURNAL OF NEUROLOGY, 2023, 30 (12) : 3722 - 3731
  • [2] A randomized, double-blind, placebo-controlled study to assess the efficacy and tolerability of gabapentin enacarbil in subjects with restless legs syndrome
    Lee, D. O.
    Ziman, R.
    Perkins, A. T.
    Poceta, J. S.
    Walters, A. S.
    DeRossett, S. E.
    Barrett, R. W.
    MOVEMENT DISORDERS, 2009, 24 : S443 - S443
  • [3] A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Tolerability of Gabapentin Enacarbil in Subjects with Restless Legs Syndrome
    Lee, Daniel O.
    Ziman, Ronald B.
    Perkins, A. Thomas
    Poceta, J. Steven
    Walters, Arthur S.
    Barrett, Ronald W.
    JOURNAL OF CLINICAL SLEEP MEDICINE, 2011, 7 (03): : 279 - 292
  • [4] A Randomized, Double-Blind, Placebo-Controlled Study To Assess the Efficacy and Tolerability of Gabapentin Enacarbil in Subjects with Restless Legs Syndrome (RLS)
    Lee, Daniel
    Ziman, Ronald
    Perkins, A. Thomas
    Poceta, J. Steven
    Walters, Arthur S.
    Barrett, Ronald W.
    NEUROLOGY, 2009, 72 (11) : A337 - A337
  • [5] A phase 2, randomized, double-blind, placebo-controlled, 48-Week study of the efficacy and safety of losmapimod in subjects with FSHD: ReDUX4
    Tawil, R.
    Wagner, K.
    NEUROMUSCULAR DISORDERS, 2021, 31 : S48 - S49
  • [6] A Randomized, Placebo-Controlled, Double-Blind Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single and Repeated Doses of Mirogabalin in Healthy Asian Volunteers
    Jansen, Mendel
    Warrington, Steven
    Dishy, Victor
    Ohwada, Shoichi
    Johnson, Lisa
    Brown, Karen
    Ishizuka, Hitoshi
    CLINICAL PHARMACOLOGY IN DRUG DEVELOPMENT, 2018, 7 (06): : 661 - 669
  • [7] Kava for generalised anxiety disorder: A 16-week double-blind, randomised, placebo-controlled study
    Sarris, Jerome
    Byrne, Gerard J.
    Bousman, Chad A.
    Cribb, Lachlan
    Savage, Karen M.
    Holmes, Oliver
    Murphy, Jenifer
    Macdonald, Patricia
    Short, Anika
    Nazareth, Sonia
    Jennings, Emma
    Thomas, Stuart
    Ogden, Edward
    Chamoli, Suneel
    Scholey, Andrew
    Stough, Con
    AUSTRALIAN AND NEW ZEALAND JOURNAL OF PSYCHIATRY, 2020, 54 (03): : 288 - 297
  • [8] Safety, Tolerability and Pharmacokinetics of Dalcetrapib Following Single and Multiple Ascending Doses in Healthy Subjects A Randomized, Double-Blind, Placebo-Controlled, Phase I Study
    Derks, Michael
    Anzures-Cabrera, Judith
    Turnbull, Lynn
    Phelan, Mary
    CLINICAL DRUG INVESTIGATION, 2011, 31 (05) : 325 - 335
  • [9] Apremilast in Pediatric Patients With Moderate to Severe Plaque Psoriasis: 16-Week Efficacy and Safety Results From the Phase 3, Randomized, Double-Blind, Placebo-Controlled SPROUT Study
    Fiorillo, Loretta
    Becker, Emily
    de Lucas, Raul
    Belloni-Fortina, Anna
    Maes, Peter
    Oberoi, Rajneet K.
    Paris, Maria
    Zhang, Wendy
    Zhang, Zuoshun
    Arkin, Lisa
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2023, 89 (03) : AB122 - AB122
  • [10] Safety and tolerability of Ganoderma lucidum in healthy subjects:: A double-blind randomized placebo-controlled trial
    Wicks, Sheila M.
    Tong, Robin
    Wang, Chong-Zhi
    O'Connor, Michael
    Karrison, Theodore
    Li, Shang
    Moss, Jonathan
    Yuan, Chun-Su
    AMERICAN JOURNAL OF CHINESE MEDICINE, 2007, 35 (03): : 407 - 414
12345